M&T Bank’s Verrica Pharmaceuticals VRCA Stock Holding History

M&T Bank’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,083	Closed	-$7.58K	–	1690
2024 Q4	$7.58K	Buy	+1,083	New	+$11.9K	﹤0.01%	1609

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return

M&T Bank's VRCA Position: Q1 2025 in Review

M&T Bank sold out of Verrica Pharmaceuticals (VRCA) in Q1 2025, closing a stake of 1,083 shares — an estimated $7.58K sold.

M&T Bank first reported a position in VRCA in Q4 2024 and held it in 1 quarter. The position peaked at $7.58K in Q4 2024. 74 funds tracked by Wall St. Rank hold VRCA as of Q1 2025.

M&T Bank reported no remaining Verrica Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
M&T Bank sold 1,083 Verrica Pharmaceuticals shares in Q1 2025, an estimated $7.58K.
M&T Bank first reported a position in Verrica Pharmaceuticals in Q4 2024 and held it in 1 quarter.
M&T Bank's Verrica Pharmaceuticals position peaked at $7.58K in Q4 2024.
74 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2025.

Based on M&T Bank's 13F filing for Q1 2025, filed 30 Apr 2025.